title: Early pituitary desensitization and ovarian suppression with leuprolide acetate is associated with in vitro fertilization-embryo transfer success.
abstract: OBJECTIVE
  To determine if the timing of the onset of pituitary desensitization and ovarian suppression using follicular phase leuprolide acetate (LA) is associated with in vitro fertilization-embryo transfer (IVF-ET) success for pregnancy.
  
  
  METHODS
  Retrospective series of IVF patients undergoing pituitary desensitization and ovarian suppression before beginning controlled ovarian hyperstimulation for IVF-ET.
  
  
  METHODS
  Tertiary infertility practice.
  
  
  METHODS
  Seventy-eight women for 80 cycles began LA on day 1 of their menstrual cycle. After 11 days of LA, 47 (59%) cycles in group I had suppressed serum estradiol (E2) levels less than 40 pg/mL, in contrast to 33 (41%) cycles in group II not adequately suppressed, thereby requiring additional days to achieve suppression.
  
  
  METHODS
  Controlled ovarian hyperstimulation was started when patients were satisfactorily suppressed, i.e., E2 less than 40 pg/mL.
  
  
  METHODS
  Mean E2 response, ampules of human menopausal gonadotropin, cancellation rates, number of oocytes retrieved, fertilization rates, and pregnancy rates (PRs) per cycle were examined between groups I and II.
  
  
  RESULTS
  Group I demonstrated a greater mean E2 response on the day of human chorionic gonadotropin 1,735 pg/mL versus 1,470 pg/mL (P = 0.008), a greater fertilization rate 64% versus 55% (P = 0.02), and a higher PR per cycle 34% versus 12% (P = 0.036) compared with group II.
  
  
  CONCLUSIONS
  Women who achieved desensitization-suppression within 11 days of initiating LA demonstrated a more favorable outcome for IVF-ET than those who did not.
authors.affiliation: Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, Connecticut.
authors.forename: D B
authors.initials: DB
authors.lastname: Seifer
authors.forename: K L
authors.initials: KL
authors.lastname: Thornton
authors.forename: A H
authors.initials: AH
authors.lastname: DeCherney
authors.forename: G
authors.initials: G
authors.lastname: Lavy
mesh_terms: D006063:Chorionic Gonadotropin / Q000494:pharmacology; D004624:Embryo Transfer; D005069:Evaluation Studies as Topic; D005260:Female; D005307:Fertilization in Vitro; D005498:Follicular Phase; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000494:pharmacology; D006728:Hormones; D006801:Humans; D016729:Leuprolide; D008596:Menotropins / Q000494:pharmacology; D010053:Ovary / Q000187:drug effects*; D010902:Pituitary Gland / Q000187:drug effects*; D011247:Pregnancy; D013997:Time Factors
chemical_list: D006063:Chorionic Gonadotropin; D006728:Hormones; D007987:Gonadotropin-Releasing Hormone; D008596:Menotropins; D016729:Leuprolide